 SVB Leerink maintains an Outperform rating on Relmada Therapeutics Inc NASDAQ: RLMD shares as the Human Liability Potential study data was about as good as we could have hoped for, with no evidence of abuse potential. Analyst Marc Goodman believes this data should give confidence to the investment community that REL-1017 will probably end up as a Schedule IV or V, which would be great news. 